CN112130381A

CN112130381A - Display panel

Info

Publication number: CN112130381A
Application number: CN201910554042.2A
Authority: CN
Inventors: 潘柏宏; 王华信
Original assignee: Lijing Photoelectric Co ltd
Current assignee: Lijing Photoelectric Co ltd; Himax Display Inc
Priority date: 2019-06-25
Filing date: 2019-06-25
Publication date: 2020-12-25

Abstract

A display panel comprises a top substrate, a bottom substrate, a display medium layer arranged between the top substrate and the bottom substrate, and a frame glue. The frame glue comprises a frame part and an injection part. The frame portion surrounds a region and a display medium layer, and the display medium layer is distributed in the region. The injection portion is connected to the frame portion. The injection part is provided with a channel path, an inner opening and an outer opening. The channel path communicates with the region at the inner opening. The outer opening is located at a distal end of the passageway remote from the region. The injection part comprises a first wall, a second wall and a third wall. The first wall is spaced from the second wall in a first direction to form an outer opening. The third wall is spaced from the second wall in a second direction to shield the outer opening.

Description

Display panel

Technical Field

The present invention relates to electronic devices, and more particularly, to a display panel.

Background

In an lcd panel, a bonding material (generally referred to as sealant) is disposed between a top substrate and a bottom substrate to form a planar cavity. The bonding material is frame-shaped and has an opening for a vacuum implantation process. In the vacuum injection process, liquid crystal molecules are introduced into the planar cavity under high vacuum through the opening. Once the planar cavity is filled with liquid crystal molecules, the opening has to be closed by a blocking material (generally called end seal). However, the interaction between the end seals and the liquid crystal molecules will affect the alignment of the liquid crystal molecules and cause moire defects in the end seals. If the display area of the liquid crystal display panel has the defect of moire at the end part for sealing, the display quality is seriously influenced.

Disclosure of Invention

The present invention provides a display panel that can eliminate or substantially reduce moire defects of end sealing of a display region of the display panel.

The display panel comprises a top substrate, a bottom substrate, a display medium layer arranged between the top substrate and the bottom substrate, and a frame glue. The frame glue comprises a frame part and an injection part. The frame portion surrounds a region and a display medium layer, and the display medium layer is distributed in the region. The injection portion is connected to the frame portion. The injection part is provided with a channel path, an inner opening and an outer opening. The channel path communicates with the region at the inner opening. The outer opening is located at a distal end of the passageway remote from the region. The injection part comprises a first wall, a second wall and a third wall. The first wall is spaced from the second wall in a first direction to form an outer opening. The third wall is spaced from the second wall in a second direction to shield the outer opening. The first direction intersects the second direction.

Based on the above, the channel path of the injection portion of the sealant is curved, and the equivalent length of the channel path can be extended. The end face seal for closing the outer opening of the channel path has a shorter length extending in the channel path than the equivalent length of the channel path of the injection part. Thus, even though the material of the display medium layer may interact with the uncured material of the end face seal, the portion of the interaction is confined to the channel path defined by the injection portion. Less influence of the end face seal, the liquid crystal molecules distributed in the display region can be aligned as expected. Therefore, the moire defect of the end sealing of the display panel can be eliminated or substantially reduced, thereby ensuring the display quality.

In order to make the aforementioned and other features and advantages of the invention more comprehensible, embodiments accompanied with figures are described in detail below.

Drawings

Fig. 1A is a top view of a display panel according to an embodiment of the invention.

FIG. 1B is a schematic sectional view taken along section line I-I' of FIG. 1A.

Fig. 2 to 21 are top views of the injection portion of the sealant of the display panel according to the embodiment of the invention.

Description of reference numerals:

102: first region

104: second region

120: top substrate

130: base substrate

140: display medium layer

150: frame glue

151: frame part

152 to 2152: injection part

160. 260, 360, 560, 660: end face seal

DD1r, DD1s, DD2s, DD2 u: end of life

DP 1-DP 21: display panel

OI1, OI2, OI3, OI4, OI5, OI 16: inner opening

OT1, OT 2: outer opening

PTH 1-PTH 21: channel path

T1a, T1b, T1c, T1p, T1 s: first bending

T2b, T2n, T2o, T2 p: second bend

T3c, T3f, T3L, T3n, T3p, T3 r: third bend

T4c, T4f, T4L, T4o, T4 p: the fourth bend

T5e, T5g, T5m, T5o, T5 r: the fifth bend

T6e, T6h, T6 m: sixth bend

T7e, T7i, T7 m: the seventh bend

T8e, T8i, T8 m: eighth bend

WL1a, WL1b, WL1 p: first wall

WL2a, WL2b, WL2n, WL2 p: second wall

WL3a, WL3b, WL3c, WL3p, WL3 s: third wall

WL4b, WL4n, WL4o, WL4 p: the fourth wall

WL5c, WL5f, WL5j, WL5n, WL5 p: fifth wall

WL6d, WL6f, WL6k, WL6o, WL6 p: sixth wall

WL7e, WL7g, WL7L, WL7 p: seventh wall

WL8e, WL8h, WL8m, WL8q, WL8r, WL8t, WL8 u: the eighth wall

WL9 i: ninth wall

WL10 i: the tenth wall

X, Y, Z: direction of rotation

Detailed Description

Fig. 1A is a top view of a display panel according to an embodiment of the invention. FIG. 1B is a schematic sectional view taken along section line I-I' of FIG. 1A. Referring to fig. 1A and 1B, the display panel DP1 has a first region 102 and a second region 104. The first region 102 has a frame-like pattern when viewed from above, and surrounds the second region 104. The first region 102 may be considered a non-display region. In some embodiments, the first region 102 can be used as a region for disposing a light shielding layer (not shown). The second area 104 is used for rendering and presenting images, and therefore, the second area 104 can be regarded as a display area.

The display panel DP1B includes a top substrate 120, a bottom substrate 130, a display medium layer 140, a sealant 150, and an end seal 160. The top substrate 120 and the bottom substrate 130 are disposed opposite to each other (open). The sealant 150 is disposed between the top substrate 120 and the bottom substrate 130, and the top substrate 120 and the bottom substrate 130 are combined by the sealant 150. The sealant 150 has a uniform thickness, so that the top substrate 120 and the bottom substrate 130 are spaced apart by a uniform distance. The display medium layer 140 distributed in the first region 102 is disposed between the top substrate 120 and the bottom substrate 130, and the display medium layer 140 is enclosed by the top substrate 120, the bottom substrate 130, the sealant 150, and the end seal 160.

The sealant 150 includes a frame portion 151 and an injection portion 152. The frame portion 151 is located in the first region 102 surrounding the second region 104, and the frame portion 151 is frame-shaped and extends substantially along the entire periphery of the display panel DP 1. The frame portion 151 has two ends (end) opposite to each other, and the injection portion 152 is connected to the two ends of the frame portion 151 opposite to each other. The injection portion 152 has a channel path PTH1, an inner opening OI1 and an outer opening OT 1. The channel path PTH1 of the injection portion 15 communicates with the second region 104 at the inner opening OI 1. The outer opening OT1 of the injection part 15 is located at the distal end of the channel path PTH1 remote from the second region 104. The dimensions of the inner opening OT1 and the outer opening OT1 of the injection portion 15 may allow the material of the display medium layer 140 to be injected into the second region 104 in a vacuum injection process (vacuum injection process) through the via PTH 1. In the present embodiment, the material of the display medium layer 140 may include liquid crystal molecules.

The injection part 152 includes a first wall WL1a, a second wall WL2a, and a third wall WL3 a. The first wall WL1a is spaced apart from the second wall WL2a in a first direction (e.g., Y direction) to form an outer opening OT 1. In other words, the outer opening OT1 is defined by one end of the first wall WL1a and one end of the second wall WL2 a. The third wall WL3a covering the outer opening OT1 is spaced apart from the second wall WL2a in a second direction (e.g., X direction) to form an inner opening OI 1. In other words, the inner opening OI1 is defined by one end of the third wall WL3a and one end of the second wall WL2 a. The third wall WL3a is located behind the outer opening OT1, but does not close off the outer opening OT1, so the outer opening OT1 may communicate with the second region 104 through a channel path PTH 1. The first wall WL1a, the second wall WL2a and the third wall WL3a define the boundaries of the injection portion 152.

The first wall WL1a intersects the third wall WL3a to form a first bend (turn) T1a of the channel path PTH 1. The third wall WL3a is connected between the first wall WL1a and one end of the frame portion 151. The second wall WL2a is connected to the other end of the frame portion 151, and the second wall WL2a is parallel to the first wall WL1 a. Although the first wall WL1a, the second wall WL2a, and the third wall WL3a are respectively straight-bar-shaped, the first wall WL1a, the second wall WL2a, and the third wall WL3a form an L-shaped passage PTH 1. Since the channel path PTH1 is curved, the equivalent length of the channel path PTH1 is substantially extended. The face seal 160 closing the outer opening OT1 of the channel-path PTH1 has a shorter length extending over the channel-path PTH1 than the equivalent length of the channel-path PTH1 of the injection portion 152. Thus, the material of dielectric layer 140 is shown to be confined within the channel path PTH1 defined by injection feature 152, even though it interacts with the uncured material of face seal 160.

In order to manufacture the display panel DP1, in the vacuum injection process, the material of the display medium layer 140 is injected into the planar cavity formed by the top substrate 120, the bottom substrate 130 and the sealant 150 through the outer opening OT 1. Once the material (e.g., liquid crystal molecules) of the display medium layer 140 fills the planar cavity, the end seal 160 is used to seal the outer opening OT 1. As described above, the liquid crystal molecules distributed in the injection part 152 may interact with the uncured material of the end face seal 160, while the liquid crystal molecules distributed in the second region 104 may not interact with the uncured material of the end face seal 160. Less of the effect of the end-face seal 160, the liquid crystal molecules distributed in the second region 104 may be aligned (origin) as desired. As a result, the moire defect (mura) of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring display quality.

The sealant 150 may be made of a light-curable material or a heat-curable material. The sealant 150 may be sprayed onto the top substrate 120 or the bottom substrate 130 by a dispenser (dispenser) or printed onto the top substrate 120 or the bottom substrate 130 by a screen printing process. To cure the sealant 150, the top substrate 120 may be transparent to allow light to pass through. In general, the material of the top substrate 120 may be glass, quartz, or other similar materials. The display panel DP1 may further include an electrode layer (not shown) disposed between the top substrate 120 and the display medium layer 140. Although the base substrate 130 shown in fig. 1B is a plate-like structure, the base substrate 130 may be a transistor array substrate including a support substrate and a transistor array. The support substrate may be, for example but not limited to, a glass plate or a silicon backplane. The transistor array may be, for example, but not limited to, a thin film transistor array (thin film transistor array) or a Complementary Metal-Oxide Semiconductor (CMOS) device array. An array of transistors (not shown) and electrode layers may be used to provide electric fields to drive and realign the display medium layer 140. The material of the display medium layer 140 may be a liquid crystal material, and thus the top substrate 120, the bottom substrate 130, the display medium layer 140, the sealant 150, and the end face seal 160 may be liquid crystal cells. In some embodiments, the Display panel DP1 may be a Thin Film Transistor Liquid Crystal Display (TFT-LCD) panel or a Liquid Crystal on Silicon (LCoS) Display panel.

In fig. 1A, a first direction (i.e., Y direction) intersects a second direction (i.e., X direction); in some embodiments, the first direction and the second direction are perpendicular to each other. In some embodiments, the first wall WL1A and the second wall WL2a shown in fig. 1A extend in one of the X-direction and the Y-direction, and the third wall WL3a extends in the other of the X-direction and the Y-direction; in some embodiments, the first wall, the second wall, and the third wall may be inclined with respect to the Y-direction or the X-direction; in some embodiments, at least one of the first wall, the second wall, and the third wall is inclined from the X-direction or the Y-direction. In some embodiments, the angle between the first wall and the third wall may be obtuse or acute. The outer opening OT1 is spread in a first direction (i.e., Y-direction) and the inner opening OI1 is spread in a second direction (i.e., X-direction).

In fig. 1A, the passage path PTH1 has a labyrinth-like structure. The exact configuration of the channel path PTH1 may vary depending on various design considerations. For example, fig. 2 to 21 are top views of the injection portion of the sealant of the display panel according to the embodiment of the invention. To clarify the differences between the following embodiments and the previous embodiments, in the following description, the same reference numerals and symbols are used to designate the same elements, and the description of the similar parts is omitted.

Specifically, the injection portion 252 shown in fig. 2 may replace the injection portion 152 shown in fig. 1A. As shown in fig. 2, the injection part 252 includes a first wall WL1b, a second wall WL2b, a third wall WL3b, and a fourth wall WL4 b. The first wall WL1b is spaced apart from the second wall WL2b in a first direction (e.g., X direction) to form an outer opening OT 2. The third wall WL3b shielding the outer opening OT2 is spaced apart from the second wall WL2b in a second direction (e.g., Y direction). The third wall WL3b is spaced apart from the frame portion 151 and the fourth wall WL4b in the first direction to form an inner opening OI 2.

The first wall WL1b is parallel to the fourth wall WL4 b; the second wall WL2b is parallel to the third wall WL3 b. The first wall WL1b and the third wall WL3b are connected to one end of the frame portion 151. The third wall WL3b is connected to one end of the first wall WL1 b. The fourth wall WL4b is connected between the second wall WL2b and the other end portion of the frame portion 151. The extending direction of the first wall WL1b intersects the extending direction of the second wall WL2b, and an outer opening OT2 is formed between one end portion of the first wall WL1b and one end portion of the second wall WL2 b. The second wall WL2b shields the inner opening OI 2.

The first wall WL1b, the second wall WL2b, the third wall WL3b, and the fourth wall WL4b define a channel path PTH 2. Although the first wall WL1b, the second wall WL2b, the third wall WL3b, and the fourth wall WL4b are respectively straight-strip-shaped, the first wall WL1b, the second wall WL2b, the third wall WL3b, and the fourth wall WL4b constitute a meandering passage path PTH 2. The first wall WL1b intersects the third wall WL3b to form a first bend T1b of the channel path PTH 2. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 2.

Since the channel path PTH2 is curved, the equivalent length of the channel path PTH2 is substantially extended. The face seal 260 extends a relatively short length in the channel-path PTH2 as compared to the equivalent length of the channel-path PTH 2. When the injection portion 252 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion of the material of the display medium layer 140 and the uncured material of the end face seal 260 is limited within the injection portion 252, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

Implant 352 of fig. 3 may be used as an alternative embodiment to implant 152 of fig. 1A. As shown in fig. 3, the injection part 352 includes a first wall WL1b, a second wall WL2b, a third wall WL3c, a fourth wall WL4b, and a fifth wall WL5 c. The first wall WL1b, the second wall WL2b, and the fourth wall WL4b of the injection part 352 may be arranged in a manner similar to the first wall WL1b, the second wall WL2b, and the fourth wall WL4b of the injection part 252, and thus the same reference numerals and symbols denote the same elements. The first wall WL1b is spaced apart from the second wall WL2b in a first direction (e.g., X direction) to form an outer opening OT 2. The third wall WL3c shielding the outer opening OT2 is spaced apart from the second wall WL2b in a second direction (e.g., Y direction). The fifth wall WL5c is spaced apart from the frame portion 151 and the first wall WL1b in the first direction to form an inner opening OI 3.

The first wall WL1b is parallel to the fourth wall WL4 b; the second wall WL2b is parallel to the third wall WL3c and the fifth wall WL5 c. The third wall WL3b is connected to a point (point) of the first wall WL1b, and this point of the first wall WL1b is located between both ends of the first wall WL1b opposite to each other. The fourth wall WL4b and the fifth wall WL5c are connected to one end portion of the frame portion 151. The extending direction of the first wall WL1b intersects the extending direction of the second wall WL2b, and an outer opening OT2 is formed between one end portion of the first wall WL1b and one end portion of the second wall WL2 b.

In the present embodiment, the channel PTH3 defined by the injection portion 352 is wrapped around in a counterclockwise direction (twist). The first wall WL1b, the second wall WL2b, the third wall WL3c, and the fourth wall WL4b define the boundaries of the injection portion 352. Although the first wall WL1b, the second wall WL2b, the third wall WL3c, the fourth wall WL4b, and the fifth wall WL5c are respectively straight strip-shaped, the first wall WL1b, the second wall WL2b, the third wall WL3c, the fourth wall WL4b, and the fifth wall WL5c constitute a meandering channel path PTH 3. The first wall WL1b intersects the third wall WL3c to form a first bend T1c of the channel path PTH 3. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 3. The fourth wall WL4b intersects the fifth wall WL5c to form a third bend T3c of the channel path PTH 3. The first wall WL1b crosses the third wall WL3c in a T-shape to form a fourth bend T4c of the channel path PTH3, and the fourth bend T4c is located on the side of the third wall WL3c opposite the first bend T1 c. Since the channel path PTH3 is curved, the equivalent length of the channel path PTH3 is substantially extended. Face seal 360 extends a relatively short length in channel-path PTH3 as compared to the equivalent length of channel-path PTH 3. When the injection portion 352 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion of the material of the display medium layer 140 and the uncured material of the end face seal 360 is confined in the injection portion 352, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The implant 452 shown in fig. 4 can be used as another embodiment instead of the implant 152 shown in fig. 1A. As shown in fig. 4, the injection part 452 further includes a sixth wall WL6d, in addition to the first wall WL1b, the second wall WL2b, the third wall WL3c, the fourth wall WL4b, and the fifth wall WL5c similar to the injection part 352 shown in fig. 3. The sixth wall WL6d is parallel to the first wall WL1b and the fourth wall WL4 b. The third wall WL3c is connected to a point of the first wall WL1b, and this point of the first wall WL1b is located between both ends of the first wall WL1b opposite to each other. The third wall WL3c is connected to a point of the sixth wall WL6d, and this point of the sixth wall WL6d is located between both ends of the sixth wall WL6d opposite to each other.

In the present embodiment, the channel PTH4 defined by the injection portion 452 is wrapped around in a counterclockwise direction. The first wall WL1b, the second wall WL2b, the third wall WL3c, and the fourth wall WL4b define the boundaries of the injection portion 452. Although the first wall WL1b to the sixth wall WL6d are respectively straight-bar-shaped, the first wall WL1b to the sixth wall WL6d constitute a meandering passage path PTH 4. The first wall WL1b intersects the third wall WL3c to form a first bend T1c of the channel path PTH 4. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 4. The fourth wall WL4b intersects the fifth wall WL5c to form a third bend T3c of the channel path PTH 4. The first wall WL1b crosses the third wall WL3c in a T-shape, and the fourth bend T4c of the channel path PTH4 is located on the side of the third wall WL3c opposite to the first bend T1 c. Since the channel path PTH4 is curved, the equivalent length of the channel path PTH4 is substantially extended. Face seal 360 extends a relatively short length in channel-path PTH4 as compared to the equivalent length of channel-path PTH 4. When the injection portion 452 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion of the material of the display medium layer 140 and the uncured material of the end face seal 160 is limited within the injection portion 452, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

Implant 552 of fig. 5 may be used as an alternative embodiment to implant 152 of fig. 1A. As shown in fig. 5, the injection part 552 further includes a seventh wall WL7e and an eighth wall WL8e, in addition to the first wall WL1b, the second wall WL2b, the third wall WL3c, the fourth wall WL4b, the fifth wall WL5c and the sixth wall WL6d similar to the injection part 452 shown in fig. 4. The seventh wall WL7e and the eighth wall WL8e are parallel to the first wall WL1b, the fourth wall WL4b and the sixth wall WL6 d. The seventh wall WL7e and the eighth wall WL8e are connected to the second wall WL2b and the fifth wall WL5c, respectively.

The first wall WL1b, the second wall WL2b, the third wall WL3c, and the fourth wall WL4b define a boundary of the injection portion 552, and the injection portion 552 defines a channel path PTH 5. Although the first wall WL1b to the eighth wall WL8e are respectively straight strip-shaped, the first wall WL1b to the eighth wall WL8e constitute a meandering passage path PTH 5. The first wall WL1b intersects the third wall WL3c to form a first bend T1c of the channel path PTH 5. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 5. The fourth wall WL4b intersects the fifth wall WL5c to form a third bend T3c of the channel path PTH 5. The first wall WL1b crosses the third wall WL3c in a T-shape, and the fourth bend T4c of the channel path PTH3 is located on the side of the third wall WL3c opposite to the first bend T1 c. The sixth wall WL6d intersects the third wall WL3c to form a fifth bend T5e and a sixth bend T6e of the channel path PTH 5. The seventh wall WL7e and the eighth wall WL8e intersect the second wall WL2b and the fifth wall WL5c, respectively, to form a seventh bend T7e and an eighth bend T8e of the channel path PTH 5. Since the channel path PTH5 is curved, the equivalent length of the channel path PTH5 is substantially extended. Face seal 560 extends a relatively short length in channel-path PTH5 as compared to the equivalent length of channel-path PTH 5. When the injection portion 552 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction between the material of the display medium layer 140 and the uncured material of the end face seal 560 is limited to the injection portion 552, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

Implant 652 of fig. 6 may be used as an alternative embodiment to implant 152 of fig. 1A. As shown in fig. 6, the injection part 652 further includes a fifth wall WL5f and a sixth wall WL6f in addition to the first wall WL1b, the second wall WL2b, the third wall WL3b and the fourth wall WL4b similar to the injection part 252 shown in fig. 2. The first wall WL1b is spaced apart from the second wall WL2b in a first direction (e.g., X direction) to form an outer opening OT 2. The third wall WL3b shielding the outer opening OT2 is spaced apart from the second wall WL2b in a second direction (e.g., Y direction). The third wall WL3b is spaced apart from the frame portion 151 and the fourth wall WL4b in the first direction to form an inner opening OI 3. The first wall WL1b is parallel to the fourth wall WL4b, the fifth wall WL5f and the sixth wall WL6 f. The second wall WL2b is parallel to the third wall WL3 b. The second wall WL2b is connected between the fourth wall WL4b and the fifth wall WL5 f. The third wall WL3b is connected between the first wall WL1b and the sixth wall WL6 f.

In the present embodiment, the channel PTH6 defined by the injection portion 652 alternatively winds back in a clockwise direction and a counterclockwise direction. The first wall WL1b, the second wall WL2b, the third wall WL3b, and the fourth wall WL4b define the boundaries of the injection portion 652. Although the first wall WL1b to the sixth wall WL6f are respectively straight-bar-shaped, the first wall WL1b to the sixth wall WL6f constitute a meandering passage path PTH 6. The first wall WL1b intersects the third wall WL3b to form a first bend T1b of the channel path PTH 6. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 6. The third wall WL3b intersects the sixth wall WL6f to form a third bend T3f of the channel path PTH 6. The second wall WL2b intersects the fifth wall WL5f to form a fourth bend T4f of the channel path PTH 6. Since the channel path PTH6 is curved, the equivalent length of the channel path PTH6 is substantially extended. Face seal 660 extends a relatively short length in channel-path PTH6 as compared to the equivalent length of channel-path PTH 6. When the injection portion 652 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion of the material of the display medium layer 140 and the uncured material of the end face seal 660 is limited within the injection portion 652, and the material of the display medium layer 140 distributed in the second region 104 can be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The implant 752 shown in fig. 7 may be used as another embodiment to replace the implant 152 shown in fig. 1A. As shown in fig. 7, the injection part 752 further includes a seventh wall WL7g in addition to the first wall WL1b, the second wall WL2b, the third wall WL3b, the fourth wall WL4b, and the fifth wall WL5f similar to the injection part 652 shown in fig. 6. The second wall WL2b is parallel to the third wall WL3b and the seventh wall WL7 g. The seventh wall WL7g is connected to the fifth wall WL5 f.

The first wall WL1b, the second wall WL2b, the third wall WL3b, and the fourth wall WL4b define a boundary of the injection portion 752, and the injection portion 752 defines a channel path PTH 7. Although the first wall WL1b to the seventh wall WL7g are respectively straight-bar-shaped, the first wall WL1b to the seventh wall WL7g constitute a meandering passage path PTH 7. The first wall WL1b intersects the third wall WL3b to form a first bend T1b of the channel path PTH 7. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 7. The third wall WL3b intersects the sixth wall WL6f to form a third bend T3f of the channel path PTH 7. The second wall WL2b intersects the fifth wall WL5f to form a fourth bend T4f of the channel path PTH 7. Since the channel path PTH7 is curved, the equivalent length of the channel path PTH7 is substantially extended. Face seal 660 extends a relatively short length in channel-path PTH7 as compared to the equivalent length of channel-path PTH 7. When the injection portion 752 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion of the material of the display medium layer 140 and the uncured material of the end face seal 660 is confined within the injection portion 752, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The injection portion 852 shown in fig. 8 may be used as another embodiment instead of the injection portion 152 shown in fig. 1A. As shown in fig. 8, the injection part 852 further includes an eighth wall WL8h, in addition to including a first wall WL1b, a second wall WL2b, a third wall WL3b, a fourth wall WL4b, a fifth wall WL5f, and a seventh wall WL7g similar to the injection part 752 shown in fig. 7. The second wall WL2b is parallel to the third wall WL3b, the seventh wall WL7g and the eighth wall WL8 h. The eighth wall WL8h is connected to the sixth wall WL6 f.

In the present embodiment, the channel PTH8 defined by the injection portion 852 alternatively winds back in a clockwise direction and a counterclockwise direction. The first wall WL1b, the second wall WL2b, the third wall WL3b, and the fourth wall WL4b define the boundaries of the injection portion 852. Although the first wall WL1b to the eighth wall WL8h are respectively straight strip-shaped, the first wall WL1b to the eighth wall WL8h constitute a meandering passage path PTH 8. The first wall WL1b intersects the third wall WL3b to form a first bend T1b of the channel path PTH 8. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 8. The third wall WL3b intersects the sixth wall WL6f to form a third bend T3f of the channel path PTH 8. The second wall WL2b intersects the fifth wall WL5f to form a fourth bend T4f of the channel path PTH 8. The seventh wall WL7g intersects the fifth wall WL5f to form a fifth bend T5g of the channel path PTH 8. The eighth wall WL8h intersects the sixth wall WL6f to form a sixth bend T6h of the channel path PTH 8. Since the channel path PTH8 is curved, the equivalent length of the channel path PTH8 is substantially extended. Face seal 660 extends a relatively short length in channel-path PTH8 as compared to the equivalent length of channel-path PTH 8. When the injection portion 852 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion of the material of the display medium layer 140 and the uncured material of the end face seal 660 is limited within the injection portion 852, and the material of the display medium layer 140 distributed in the second region 104 can be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The injection portion 952 shown in fig. 9 may be used as another embodiment instead of the injection portion 152 shown in fig. 1A. As shown in fig. 9, the injection part 952 includes a ninth wall WL9i and a tenth wall WL10i, in addition to a first wall WL1b, a second wall WL2b, a third wall WL3b, a fourth wall WL4b, a fifth wall WL5f, a seventh wall WL7g, and an eighth wall WL8h similar to the injection part 852 shown in fig. 8. The second wall WL2b is parallel to the third wall WL3b, the seventh wall WL7g, the eighth wall WL8h, the ninth wall WL9i and the tenth wall WL10 i. The ninth wall WL9i is connected to the sixth wall WL6f and the eighth wall WL8 h. The tenth wall WL10i is connected to the fourth wall WL4b and one end portion of the frame portion 151.

The first wall WL1b, the second wall WL2b, the third wall WL3b and the fourth wall WL4b define the boundary of the injection portion 952, and the injection portion 952 defines a channel path PTH 9. Although the first wall WL1b to the tenth wall WL10i are respectively straight-bar-shaped, the first wall WL1b to the tenth wall WL10i constitute a meandering passage path PTH 9. The first wall WL1b intersects the third wall WL3b to form a first bend T1b of the channel path PTH 9. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 9. The third wall WL3b intersects the sixth wall WL6f to form a third bend T3f of the channel path PTH 9. The second wall WL2b intersects the fifth wall WL5f to form a fourth bend T4f of the channel path PTH 9. The seventh wall WL7g intersects the fifth wall WL5f to form a fifth bend T5g of the channel path PTH 9. The eighth wall WL8h intersects the sixth wall WL6f to form a sixth bend T6h of the channel path PTH 9. The ninth wall WL9i intersects the sixth wall WL6f to form a seventh bend T7i of the channel path PTH 9. The tenth wall WL10i intersects the fourth wall WL4b to form an eighth bend T8i of the channel path PTH 9. Since the channel path PTH9 is curved, the equivalent length of the channel path PTH9 is substantially extended. Face seal 660 extends a relatively short length in channel-path PTH9 as compared to the equivalent length of channel-path PTH 9. When the injection portion 952 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion between the material of the display medium layer 140 and the uncured material of the end face seal 660 is confined in the injection portion 952, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The injection portion 1052 shown in fig. 10 may be used as another embodiment instead of the injection portion 152 shown in fig. 1A. As shown in fig. 10, the injection part 1052, in addition to including a first wall WL1b, a second wall WL2b, a third wall WL3b, and a fourth wall WL4b similar to the injection part 252 shown in fig. 2, also includes a fifth wall WL5 j. The first wall WL1b is spaced apart from the second wall WL2b in a first direction (e.g., X direction) to form an outer opening OT 2. The third wall WL3b shielding the outer opening OT2 is spaced apart from the second wall WL2b in a second direction (e.g., Y direction). The third wall WL3b is spaced apart from the frame portion 151 and the fourth wall WL4b in the first direction to form an inner opening OI 2. The first wall WL1b is parallel to the fourth wall WL4b and the fifth wall WL5 j. The second wall WL2b is parallel to the third wall WL3 b. The fifth wall WL5j is connected to a point of the second wall WL2b, and this point of the second wall WL2b is located between both ends of the second wall WL2b opposite to each other. The first wall WL1b and the third wall WL3b are connected to one end of the frame portion 151. The fourth wall WL4b is connected between the second wall WL2b and the other end portion of the frame portion 151.

The first wall WL1b, the second wall WL2b, the third wall WL3b and the fourth wall WL4b define the boundaries of the injection portion 1052, while the injection portion 1052 defines a channel path PTH 10. Although the first wall WL1b to the fifth wall WL5j are respectively straight-bar-shaped, the first wall WL1b to the fifth wall WL5j constitute a meandering passage path PTH 10. The first wall WL1b intersects the third wall WL3b to form a first bend T1b of the channel path PTH 10. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 10. Since the channel path PTH10 is curved, the equivalent length of the channel path PTH10 is substantially extended. The face seal 260 extends a relatively short length in the channel-path PTH10 as compared to the equivalent length of the channel-path PTH 10. When injection portion 1052 is applied to display panel DP1 shown in fig. 1A and 1B, the portion of the material of display medium layer 140 interacting with the uncured material of end face seal 260 is confined within injection portion 1052, and the material of display medium layer 140 distributed in second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The injection portion 1152 shown in fig. 11 may be used as another embodiment instead of the injection portion 152 shown in fig. 1A. As shown in fig. 11, sprue 1152 is substantially similar to sprue 1052 shown in fig. 10, and sprue 652 further includes a sixth wall WL6k as compared to sprue 1052 shown in fig. 10. The second wall WL2b is parallel to the third wall WL3b and the sixth wall WL6 k. The fifth wall WL5j is connected to the sixth wall WL6k and the second wall WL2 b.

The first wall WL1b, the second wall WL2b, the third wall WL3b, and the fourth wall WL4b define the boundaries of the injection portion 1152, and the injection portion 1152 defines a channel path PTH 11. Although the first wall WL1b to the sixth wall WL6k are respectively straight-bar-shaped, the first wall WL1b to the sixth wall WL6k constitute a meandering passage path PTH 11. The first wall WL1b intersects the third wall WL3b to form a first bend T1b of the channel path PTH 11. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 11. Since the channel path PTH11 is curved, the equivalent length of the channel path PTH11 is substantially extended. Face seal 1160 extends a relatively short length in channel-path PTH11 as compared to the equivalent length of channel-path PTH 11. When the injection portion 1152 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion of the material of the display medium layer 140 and the uncured material of the end face seal 1160 is confined in the injection portion 1152, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

Implant 1252 of fig. 12 may be used as an alternative embodiment to implant 152 of fig. 1A. As shown in fig. 12, the injection part 1252 further includes a seventh wall WL7L, in addition to the first wall WL1b, the second wall WL2b, the third wall WL3b, the fourth wall WL4b, the fifth wall WL5j, and the sixth wall WL6k similar to the injection part 1152 shown in fig. 11. The first wall WL1b is parallel to the fourth wall WL4b, the fifth wall WL5j and the seventh wall WL 7L. The seventh wall WL7L is connected to the third wall WL3 b.

First wall WL1b, second wall WL2b, third wall WL3b, and fourth wall WL4b define the boundaries of injection 1252, while injection 1252 defines a channel path PTH 12. Although the first wall WL1b to the seventh wall WL7L are respectively straight-bar-shaped, the first wall WL1b to the seventh wall WL7L constitute a meandering passage path PTH 12. The first wall WL1b intersects the third wall WL3b to form a first bend T1b of the channel path PTH 12. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 12. The seventh wall WL7L intersects the third wall WL3b to form a third bend T3L of the channel path PTH 12. The fifth wall WL5j intersects the second wall WL2b to form a fourth bend T4L of the channel path PTH 12. Since the channel path PTH12 is curved, the equivalent length of the channel path PTH12 is substantially extended. Face seal 1160 extends a relatively short length in channel-path PTH12 as compared to the equivalent length of channel-path PTH 12. When the injection portion 1252 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction between the material of the display medium layer 140 and the uncured material of the end-face seal 1160 is partially confined in the injection portion 1252, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The injection portion 1352 shown in fig. 13 may be used as another embodiment instead of the injection portion 152 shown in fig. 1A. As shown in fig. 13, the injector 1352 further includes an eighth wall WL8m in addition to the first wall WL1b, the second wall WL2b, the third wall WL3b, the fourth wall WL4b, the fifth wall WL5j, the sixth wall WL6k, and the seventh wall WL7L similar to the injector 1252 shown in fig. 12. The second wall WL2b is parallel to the third wall WL3b, the sixth wall WL6k and the eighth wall WL8 m. The eighth wall WL8m is connected to a point of the first wall WL1b, and this point of the first wall WL1b is located between both ends of the first wall WL1b opposite to each other.

The first wall WL1b, the second wall WL2b, the third wall WL3b, and the fourth wall WL4b define the boundaries of the injection portion 1352, while the injection portion 1352 defines a channel path PTH 13. Although the first wall WL1b to the eighth wall WL8m are respectively straight strip-shaped, the first wall WL1b to the eighth wall WL8m constitute a meandering passage path PTH 13. The first wall WL1b intersects the third wall WL3b to form a first bend T1b of the channel path PTH 13. The fourth wall WL4b intersects the second wall WL2b to form a second bend T2b of the channel path PTH 13. The seventh wall WL7L intersects the third wall WL3b to form a third bend T3L of the channel path PTH 13. The fifth wall WL5j intersects the second wall WL2b to form a fourth bend T4L of the channel path PTH 13. The sixth wall WL6k intersects the fifth wall WL5j to form a fifth bend T5m of the channel path PTH 13. The fifth wall WL5j intersects the second wall WL2b to form a sixth bend T6m of the channel path PTH 13. The eighth wall WL8m intersects the first wall WL1b to form a seventh bend T7m and an eighth bend T8m of the channel path PTH 13. Since the channel path PTH13 is curved, the equivalent length of the channel path PTH13 is substantially extended. Face seal 1360 extends a relatively short length in channel-path PTH13 as compared to the equivalent length of channel-path PTH 13. When the injection portion 1352 is applied to the display panel DP1 shown in fig. 1A and 1B, the portion of the material of the display medium layer 140 interacting with the uncured material of the end seal 1360 is confined in the injection portion 1352, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The injection portion 1452 shown in fig. 14 may be used as another embodiment instead of the injection portion 152 shown in fig. 1A. As shown in fig. 14, the injection part 1452 includes a first wall WL1a, a second wall WL2n, a third wall WL3a, a fourth wall WL4n, and a fifth wall WL5 n. The first wall WL1a and the third wall WL3a of the injection part 1452 may be arranged in a similar manner to the first wall WL1a and the third wall WL3a of the injection part 152, and thus the same reference numerals and symbols denote the same elements. The first wall WL1a is spaced apart from the second wall WL2n in a first direction (e.g., Y direction) to form an outer opening OT 1. The third wall WL3a shielding the outer opening OT1 is spaced apart from the second wall WL2n in a second direction (e.g., X direction). The fourth wall WL4n is spaced apart from the frame portion 151 and the second wall WL2n in the second direction to form an inner opening OI 4.

The first wall WL1a is parallel to the fourth wall WL4n and the fifth wall WL5 n. The second wall WL2n is parallel to the third wall WL3 a. The third wall WL3a is connected between the first wall WL1a and one end of the frame portion 151, and the third wall WL3a and the fourth wall WL4n are connected to this end of the frame portion 151. The second wall WL2n is connected between the fifth wall WL5n and the other end portion of the frame portion 151. The extending direction of the first wall WL1a intersects the extending direction of the second wall WL2n, and an outer opening OT1 is formed between one end of the first wall WL1a and one end of the second wall WL2 n. The fifth wall WL5n shields the inner opening OI 4.

The first wall WL1a, the second wall WL2n, the third wall WL3a, and the fourth wall WL4n define the boundaries of the injection portion 1452, and the injection portion 1452 defines a channel path PTH 14. Although the first wall WL1a, the second wall WL2n, the third wall WL3a, the fourth wall WL4n, and the fifth wall WL5n are respectively straight strip-shaped, the first wall WL1a, the second wall WL2n, the third wall WL3a, the fourth wall WL4n, and the fifth wall WL5n constitute a meandering channel path PTH 14. The first wall WL1a intersects the third wall WL3a to form a first bend T1a of the channel path PTH 14. The fourth wall WL4n intersects the third wall WL3a to form a second bend T2n of the channel path PTH 14. The fifth wall WL5n intersects the second wall WL2n to form a third bend T3n of the channel path PTH 14. Since the channel path PTH14 is curved, the equivalent length of the channel path PTH14 is substantially extended. The face seal 1460 extends a relatively short length in the channel-path PTH14 as compared to the equivalent length of the channel-path PTH 14. When the injection portion 1452 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction between the material of the display medium layer 140 and the uncured material of the end-face seal 1460 is partially confined in the injection portion 1452, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

Implant 1552 of FIG. 15 may be used as an alternative embodiment to implant 152 of FIG. 1A. As shown in fig. 15, the injection part 1552 includes a first wall WL1a, a second wall WL2n, a third wall WL3a, a fourth wall WL4o, a fifth wall WL5n, and a sixth wall WL6 o. The first wall WL1a, the second wall WL2n, the third wall WL3a, and the fifth wall WL5n of the injection part 1452 may be arranged in a manner similar to the first wall WL1a, the third wall WL3a, and the second wall WL2n, the fifth wall WL5n of the injection part 152, and thus the same reference numerals and symbols denote the same elements. The first wall WL1a is spaced apart from the second wall WL2n in a first direction (e.g., Y direction) to form an outer opening OT 1. The third wall WL3a shielding the outer opening OT1 is spaced apart from the second wall WL2n in a second direction (e.g., X direction). The sixth wall WL6o is spaced apart from the frame portion 151 and the third wall WL3a in the second direction to form an inner opening OI 5.

The first wall WL1a is parallel to the fourth wall WL4 o. A fifth wall WL5n and a sixth wall WL6 o. The second wall WL2n is parallel to the third wall WL3 a. The third wall WL3a is connected between the first wall WL1a and one end of the frame portion 151. The fourth wall WL4o is connected to a point of the third wall WL3a, and this point of the third wall WL3a is located between both ends of the third wall WL3a opposite to each other. The second wall WL2n is connected between the fifth wall WL5n and the sixth wall WL6o, and the second wall WL2n and the sixth wall WL6o are connected to the other end portion of the frame portion 151. The extending direction of the first wall WL1a intersects the extending direction of the second wall WL2 n. An outer opening OT1 is formed between one end of the first wall WL1a and one end of the second wall WL2 n. The fourth wall WL4o shields the inner opening OI 5.

In the present embodiment, the channel PTH15 defined by the injection portion 1552 alternatively wraps around in a clockwise direction and a counter-clockwise direction. The first wall WL1a, the second wall WL2n, the third wall WL3a, and the fourth wall WL4o define boundaries of the injection part 1552, and the injection part 1552 defines a channel path PTH 15. Although the first wall WL1a, the second wall WL2n, the third wall WL3a, the fourth wall WL4o, the fifth wall WL5n, and the sixth wall WL6o are respectively straight strip-shaped, the first wall WL1a, the second wall WL2n, the third wall WL3a, the fourth wall WL4o, the fifth wall WL5n, and the sixth wall WL6o constitute a meandering channel PTH 15. The first wall WL1a intersects the third wall WL3a to form a first bend T1a of the channel path PTH 15. The fourth wall WL4o intersects the third wall WL3a to form a second bend T2o of the channel path PTH 15. The fifth wall WL5n intersects the second wall WL2n to form a third bend T3n of the channel path PTH 15. The second wall WL2n intersects the sixth wall WL6o to form a fourth bend T4o of the channel path PTH 15. The fourth wall WL4o intersects the third wall WL3a to form a fifth bend T5o of the channel path PTH 15. Since the channel path PTH15 is curved, the equivalent length of the channel path PTH15 is substantially extended. Face seal 1560 extends a relatively short length in channel-path PTH15 as compared to the equivalent length of channel-path PTH 15. When the injection part 1552 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction between the material of the display medium layer 140 and the uncured material of the end seal 1560 is limited to the injection part 1552, and the material of the display medium layer 140 distributed in the second region 104 can be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The injection portion 1652 shown in fig. 16 may be used as another embodiment instead of the injection portion 152 shown in fig. 1A. As shown in fig. 16, the injection portion 1652 includes a first wall WL1p, a second wall WL2p, a third wall WL3p, a fourth wall WL4p, a fifth wall WL5p, a sixth wall WL6p, and a seventh wall WL7 p. The first wall WL1p is spaced apart from the second wall WL2p in a second direction (e.g., the X direction) to form an outer opening OT 16. The third wall WL3p shielding the outer opening OT16 is spaced apart from the first wall WL1p and the second wall WL2p in a first direction (e.g., Y direction). The sixth wall WL6p is spaced apart from the seventh wall WL7p in the second direction to form an inner opening OI 16. The third wall WL3p shields the inner opening OI 16.

The third wall WL3p is parallel to the first wall WL1p and the second wall WL2 p. The channel path PTH16 branches from the outer opening OT16 into a first portion between the first wall WL1p and the third wall WL3p and a second portion between the second wall WL2p and the third wall WL3 p. Similarly, the third wall WL3p is parallel to the sixth wall WL6p and the seventh wall WL7 p. The passage path PTH16 branches from the inner opening OI16 into a third portion between the sixth wall WL6p and the third wall WL3p and a fourth portion between the seventh wall WL7p and the third wall WL3 p. The fourth wall WL4n is parallel to the fifth wall WL5 n.

The fourth wall WL4p is connected between one end of the frame portion 151 and the second wall WL2p, and the fourth wall WL4p and the sixth wall WL6p are connected to this end of the frame portion 151. The fifth wall WL5p is connected between the other end of the frame portion 151 and the first wall WL1p, and the fifth wall WL5p and the seventh wall WL7p are connected to this end of the frame portion 151. The first wall WL1p, the second wall WL2p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p, and the seventh wall WL7p surround the injection portion 1652. The third wall WL3p is spaced apart from the first wall WL1p, the second wall WL2p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p and the seventh wall WL7 p. In this embodiment, the third wall WL3p is isolated and independent.

First wall WL1p, second wall WL2p, fourth wall WL4p, fifth wall WL5p, sixth wall WL6p and seventh wall WL7p define the boundary of injection portion 1652, and injection portion 1652 defines a channel path PTH 16. Although the first wall WL1p, the second wall WL2p, the third wall WL3p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p, and the seventh wall WL7p are respectively straight strip-shaped, the first wall WL1p, the second wall WL2p, the third wall WL3p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p, and the seventh wall WL7p form a meandering channel path PTH 16. The first wall WL1p intersects the fifth wall WL5p to form a first bend T1p of the channel path PTH 16. The second wall WL2p intersects the fourth wall WL4p to form a second bend T2p of the channel path PTH 16. The fifth wall WL5p intersects the seventh wall WL7p to form a third bend T3p of the channel path PTH 16. The fourth wall WL4p intersects the sixth wall WL6p to form a fourth bend T4p of the channel path PTH 16. Since the channel path PTH16 is curved, the equivalent length of the channel path PTH16 is substantially extended. Face seal 1660 extends a relatively short length in channel-path PTH16 as compared to the equivalent length of channel-path PTH 16. When the injection portion 1652 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion of the material of the display medium layer 140 and the uncured material of the end seal 1660 is limited to the injection portion 1652, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The injection portion 1752 shown in fig. 17 may be used as another embodiment instead of the injection portion 152 shown in fig. 1A. As shown in fig. 17, injection portion 1752 includes eighth wall WL8q in addition to first wall WL1p, second wall WL2p, third wall WL3p, fourth wall WL4p, fifth wall WL5p, sixth wall WL6p, and seventh wall WL7p similar to injection portion 1652 shown in fig. 16. The eighth wall WL8q is parallel to the third wall WL3p and shields the inner opening OI16, and the eighth wall WL8q is parallel to the sixth wall WL6p and the seventh wall WL7 p. The passage path PTH17 branches from the inner opening OI16 into a third portion between the sixth wall WL6p and the eighth wall WL8q and a fourth portion between the seventh wall WL7p and the eighth wall WL8 q. The third wall WL3p and the eighth wall WL8q are spaced apart from the first wall WL1p, the second wall WL2p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p and the seventh wall WL7 p. The third wall WL3p and the eighth wall WL8q are located in a region surrounded by the first wall WL1p, the second wall WL2p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p, and the seventh wall WL7p and are spaced apart from each other in the first direction (e.g., the Y direction). In this embodiment, the third wall WL3p and the eighth wall WL8q are isolated and independent.

First wall WL1p, second wall WL2p, fourth wall WL4p, fifth wall WL5p, sixth wall WL6p, and seventh wall WL7p define a boundary of injector 1752, and injector 1752 defines a channel path PTH 17. The first wall WL1p intersects the fifth wall WL5p to form a first bend T1p of the channel path PTH 17. The second wall WL2p intersects the fourth wall WL4p to form a second bend T2p of the channel path PTH 17. The fifth wall WL5p intersects the seventh wall WL7p to form a third bend T3p of the channel path PTH 17. The fourth wall WL4p intersects the sixth wall WL6p to form a fourth bend T4p of the channel path PTH 17. Although the first wall WL1p to the eighth wall WL8q are respectively straight strip-shaped, the first wall WL1p to the eighth wall WL8q constitute a meandering passage path PTH 17. Since the channel path PTH17 is curved, the equivalent length of the channel path PTH17 is substantially extended. Face seal 1660 extends a relatively short length in channel-path PTH17 as compared to the equivalent length of channel-path PTH 17. When the injection portion 1752 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction portion of the material of the display medium layer 140 and the uncured material of the end face seal 1660 is limited within the injection portion 1752, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

Implant 1852 of FIG. 18 may be used as an alternative embodiment to implant 152 of FIG. 1A. As shown in fig. 18, injection portion 1852 further includes eighth wall WL8r in addition to first wall WL1p, second wall WL2p, third wall WL3p, fourth wall WL4p, fifth wall WL5p, sixth wall WL6p, and seventh wall WL7p similar to injection portion 1652 shown in fig. 16. The eighth wall WL8r is parallel to the third wall WL3p and shields the inner opening OI16, and the eighth wall WL8r is parallel to the sixth wall WL6p and the seventh wall WL7 p. The passage path PTH18 branches from the inner opening OI16 into a third portion between the sixth wall WL6p and the eighth wall WL8r and a fourth portion between the seventh wall WL7p and the eighth wall WL8 r. The eighth wall WL8r is connected to the fifth wall WL5p and is spaced apart from the fourth wall WL4 p. The eighth wall WL8r is connected to a point of the fifth wall WL5p, and this point of the fifth wall WL5p is located between both ends of the fifth wall WL5p opposite to each other. The eighth wall WL8r, the fifth wall WL5p, and the seventh wall WL7p form a dead end DD1r of the channel-path PTH 18.

The first wall WL1p, the second wall WL2p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p and the seventh wall WL7p define the boundaries of an injection section 1852, and the injection section 1852 defines a channel path PTH 18. Although the first wall WL1p to the eighth wall WL8r are respectively straight strip-shaped, the first wall WL1p to the eighth wall WL8r constitute a meandering passage path PTH 18. The first wall WL1p intersects the fifth wall WL5p to form a first bend T1p of the channel path PTH 18. The second wall WL2p intersects the fourth wall WL4p to form a second bend T2p of the channel path PTH 18. The fifth wall WL5p intersects the eighth wall WL8r to form a third bend T3r of the channel path PTH 18. The fourth wall WL4p intersects the sixth wall WL6p to form a fourth bend T4p of the channel path PTH 18. The fifth wall WL5p intersects the eighth wall WL8r to form a fifth bend T5r of the channel path PTH 18. Since the channel path PTH18 is curved, the equivalent length of the channel path PTH18 is substantially extended. Face seal 1660 extends a relatively short length in channel-path PTH18 as compared to the equivalent length of channel-path PTH 18. When the injection portion 1852 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction between the material of the display medium layer 140 and the uncured material of the end seal 1660 is partially confined in the injection portion 1852, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

Implant 1952 of FIG. 19 can be replaced with implant 152 of FIG. 1A as an alternative embodiment. As shown in fig. 19, the injection part 1952 includes a first wall WL1p, a second wall WL2p, a third wall WL3s, a fourth wall WL4p, a fifth wall WL5p, a sixth wall WL6p, and a seventh wall WL7 p. The first wall WL1p, the second wall WL2p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p, and the seventh wall WL7p of the injection part 1452 may be arranged in a manner similar to the first wall WL1p, the second wall WL2p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p, and the seventh wall WL7p of the injection part 1652, and thus the same reference numerals and symbols denote the same elements. The third wall WL3s shielding the outer opening OT16 and the inner opening OI16 is spaced apart from the first wall WL1p and the second wall WL2p in a first direction (e.g., Y direction).

The third wall WL3s is parallel to the first wall WL1p and the second wall WL2 p. The channel path PTH19 branches from the outer opening OT16 into a first portion between the first wall WL1p and the third wall WL3s and a second portion between the second wall WL2p and the third wall WL3 s. Similarly, the third wall WL3s is parallel to the sixth wall WL6p and the seventh wall WL7 p. The passage path PTH19 branches from the inner opening OI16 into a third portion between the sixth wall WL6p and the third wall WL3s and a fourth portion between the seventh wall WL7p and the third wall WL3 s. The third wall WL3s is connected to the fifth wall WL5p and is spaced apart from the fourth wall WL4 p. The third wall WL3s is connected to a point of the fifth wall WL5p, and this point of the fifth wall WL5p is located between both ends of the fifth wall WL5p opposite to each other. The third wall WL3s, the fifth wall WL5p, and the seventh wall WL7p form a dead end DD1s of the channel path PTH 19. The first wall WL1p, the third wall WL3s, and the fifth wall WL5p form a dead end DD2s of the channel path PTH 19.

First wall WL1p, second wall WL2p, fourth wall WL4p, fifth wall WL5p, sixth wall WL6p, and seventh wall WL7p define the boundaries of injection section 1952, and injection section 1952 defines a channel path PTH 19. Although the first wall WL1p, the second wall WL2p, the third wall WL3s, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p, and the seventh wall WL7p are respectively straight strip-shaped, the first wall WL1p, the second wall WL2p, the third wall WL3s, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p, and the seventh wall WL7p constitute a meandering channel path PTH 19. The third wall WL3s intersects the fifth wall WL5p to form a first bend T1s of the channel path PTH 19. The second wall WL2p intersects the fourth wall WL4p to form a second bend T2p of the channel path PTH 19. The fifth wall WL5p intersects the seventh wall WL7p to form a third bend T3r of the channel path PTH 19. The fourth wall WL4p intersects the sixth wall WL6p to form a fourth bend T4p of the channel path PTH 19. Since the channel path PTH19 is curved, the equivalent length of the channel path PTH19 is substantially extended. Face seal 1660 extends a relatively short length in channel-path PTH19 as compared to the equivalent length of channel-path PTH 19. When the injection portion 1952 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction between the material of the display medium layer 140 and the uncured material of the end seal 1660 is partially confined in the injection portion 1952, and the material of the display medium layer 140 distributed in the second region 104 can be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The implant 2052 shown in fig. 20 may be used as another embodiment instead of the implant 152 shown in fig. 1A. As shown in fig. 20, the injection part 2052 includes an eighth wall WL8t in addition to the injection part 1952 shown in fig. 19. The eighth wall WL8t is parallel to the third wall WL3s and shields the inner opening OI16, and the eighth wall WL8t is parallel to the sixth wall WL6p and the seventh wall WL7 p. The passage path PTH20 branches from the inner opening OI16 into a third portion between the sixth wall WL6p and the eighth wall WL8t and a fourth portion between the seventh wall WL7p and the eighth wall WL8 t. The eighth wall WL8t is spaced apart from the first wall WL1p, the second wall WL2p, the third wall WL3s, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p and the seventh wall WL7 p. In this embodiment, the eighth wall WL8t is isolated and independent.

First wall WL1p, second wall WL2p, fourth wall WL4p, fifth wall WL5p, sixth wall WL6p, and seventh wall WL7p define the boundaries of injection port 2052, and injection port 2052 defines a passage path PTH 20. Although the first wall WL1p to the eighth wall WL8t are respectively straight strip-shaped, the first wall WL1p to the eighth wall WL8t constitute a meandering passage path PTH 20. The third wall WL3s intersects the fifth wall WL5p to form a first bend T1s of the channel path PTH 20. The second wall WL2p intersects the fourth wall WL4p to form a second bend T2p of the channel path PTH 20. The fifth wall WL5p intersects the seventh wall WL7p to form a third bend T3p of the channel path PTH 20. The fourth wall WL4p intersects the sixth wall WL6p to form a fourth bend T4p of the channel path PTH 20. The fifth wall WL5p intersects the third wall WL3s to form a fifth bend T5T of the channel path PTH 18. Since the channel path PTH20 is curved, the equivalent length of the channel path PTH20 is substantially extended. Face seal 1660 extends a relatively short length in channel-path PTH20 as compared to the equivalent length of channel-path PTH 20. When the injection portion 2052 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction between the material of the display medium layer 140 and the uncured material of the end seal 1660 is partially confined in the injection portion 2052, and the material of the display medium layer 140 distributed in the second region 104 can be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

The injection part 2152 shown in fig. 21 may be used as another embodiment instead of the injection part 152 shown in fig. 1A. As shown in fig. 21, the injection part 2152 includes an eighth wall WL8u in addition to the injection part 1952 shown in fig. 19. The eighth wall WL8u is parallel to the third wall WL3s and shields the inner opening OI 16. The eighth wall WL8u is parallel to the sixth wall WL6p and the seventh wall WL7 p. The passage path PTH21 branches from the inner opening OI16 into a third portion between the sixth wall WL6p and the eighth wall WL8u and a fourth portion between the seventh wall WL7p and the eighth wall WL8 u. The eighth wall WL8u is connected to the fourth wall WL4p and is spaced apart from the fifth wall WL5 p. In addition, the third wall WL3s is connected to the fifth wall WL5p, and the eighth wall WL8u is connected to the fourth wall WL4 p. The eighth wall WL8u is connected to a point of the fourth wall WL4p, and this point of the fourth wall WL4p is located between both ends of the fourth wall WL4p opposite to each other. The second wall WL2p, the fourth wall WL4p and the eighth wall WL8u form a dead end DD2u of the channel-path PTH 21.

In the present embodiment, the injection portion 2152 defines a passage PTH21 that alternately loops in a clockwise direction and a counterclockwise direction. The first wall WL1p, the second wall WL2p, the fourth wall WL4p, the fifth wall WL5p, the sixth wall WL6p and the seventh wall WL7p define the boundaries of the injection portion 2152, while the injection portion 2152 defines a channel path PTH 21. Although the first wall WL1p to the eighth wall WL8u are respectively straight strip-shaped, the first wall WL1p to the eighth wall WL8u constitute a meandering passage path PTH 21. The third wall WL3s intersects the fifth wall WL5p to form a first bend T1s of the channel path PTH 21. The second wall WL2p intersects the fourth wall WL4p to form a second bend T2p of the channel path PTH 21. The fifth wall WL5p intersects the seventh wall WL7p to form a third bend T3p of the channel path PTH 21. The fourth wall WL4p intersects the eighth wall WL8u to form a fourth bend T4u of the channel path PTH 21. The fifth wall WL5p intersects the third wall WL3s to form a fifth bend T5T of the channel path PTH 21. Since the channel path PTH21 is curved, the equivalent length of the channel path PTH21 is substantially extended. Face seal 1660 extends a relatively short length in channel-path PTH21 as compared to the equivalent length of channel-path PTH 21. When the injection part 2152 is applied to the display panel DP1 shown in fig. 1A and 1B, the interaction between the material of the display medium layer 140 and the uncured material of the end seal 1660 is partially confined in the injection part 2152, and the material of the display medium layer 140 distributed in the second region 104 may be aligned as desired. As a result, the moire defect of the end seal of the display panel DP1 can be eliminated or substantially reduced, thereby ensuring the display quality.

In summary, the channel path of the injection portion of the sealant is curved, so that the equivalent length of the channel path can be extended. The end face seal for closing the outer opening of the channel path has a shorter length extending in the channel path than the equivalent length of the channel path of the injection part. Thus, the material of the display medium layer may interact with the uncured material of the end face seal even though, however, once interaction occurs, the portion of the interaction is confined to the channel path defined by the injection portion. Less influence of the end face seal, the liquid crystal molecules distributed in the display region can be aligned as expected. Therefore, the moire defect of the end sealing of the display panel can be eliminated or substantially reduced, thereby ensuring the display quality.

Although the present invention has been described with reference to the above embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention.

Claims

1. A display panel, comprising:

a top substrate;

a base substrate;

a display medium layer disposed between the top substrate and the bottom substrate; and

a sealant, comprising:

a frame portion surrounding a region and the display medium layer, wherein the display medium layer is distributed in the region; and

the injection part is connected to the frame part and is provided with a channel path, an inner opening and an outer opening, the channel path is communicated with the area at the inner opening, the outer opening is positioned at the far end part of the channel path far away from the area, the injection part comprises a first wall, a second wall and a third wall, the first wall is separated from the second wall in a first direction to form the outer opening, the third wall is separated from the second wall in a second direction to shield the outer opening, and the first direction is crossed with the second direction.

2. The display panel of claim 1, wherein the first wall intersects the third wall to form a first bend of the channel path.

3. The display panel of claim 1, wherein an extending direction of the first wall intersects an extending direction of the second wall, and the outer opening is formed between an end portion of the first wall and an end portion of the second wall.

4. The display panel of claim 1, wherein the first wall and the third wall are connected to the frame portion.

5. The display panel of claim 4, wherein the third wall is connected to an end of the first wall.

6. The display panel of claim 1, wherein the third wall is connected to a point of the first wall, and the point is located between two ends of the first wall opposite to each other.

7. The display panel of claim 1, wherein the third wall is spaced apart from the frame portion in the first direction to form the inner opening.

8. The display panel of claim 1, wherein the third wall shields the inner opening.

9. The display panel of claim 1, wherein the third wall is connected between the first wall and the frame portion.

10. The display panel of claim 1, wherein the sealant further comprises a fourth wall intersecting the third wall to form a second bend of the channel path.

11. The display panel of claim 10, wherein the fourth wall is spaced apart from the frame portion in the first direction to form the inner opening.

12. The display panel of claim 10, wherein the fourth wall is connected to the third wall.

13. The display panel of claim 1, wherein the first wall is parallel to the second wall.

14. The display panel of claim 1, wherein the sealant further comprises a fourth wall and a fifth wall, the fourth wall is connected between the frame portion and the first wall, the fifth wall is connected between the frame portion and the second wall, and the first wall, the second wall, the fourth wall, and the fifth wall surround the injection portion.

15. The display panel of claim 14, wherein the third wall is spaced apart from the first wall, the second wall, the fourth wall, and the fifth wall.

16. The display panel of claim 14, wherein the third wall is connected to one of the fourth wall and the fifth wall, and the third wall is spaced apart from the other of the fourth wall and the fifth wall.

17. The display panel of claim 14, wherein the sealant further includes a sixth wall, and the sixth wall and the third wall are located in another region surrounded by the first wall, the second wall, the fourth wall and the fifth wall and are spaced apart from each other in the second direction.

18. The display panel of claim 17, wherein the sixth wall and the third wall are spaced apart from the first wall, the second wall, the fourth wall, and the fifth wall.

19. The display panel of claim 17, wherein the third wall is connected to one of the fourth wall and the fifth wall, and the sixth wall is connected to the other of the fourth wall and the fifth wall.

20. The display panel of claim 1, wherein the second wall is spaced apart from the third wall in the second direction to form the inner opening.

21. The display panel of claim 1, wherein the third wall is parallel to the first wall and the second wall, and the channel path branches from an outer opening in a first portion between the first wall and the third wall and a second portion between the first wall and the third wall.